-
-
-
Loading
Loading
After the perkcession ends, a perkcovery will surely follow
A flurry of deals suggests that drug firms favour buying their way out of trouble
It is struggling to use nearly €200bn of EU cash
It is too cosy at the top of the memory-chip market